Biotech Saniona has made significant advances on several fronts during the last twelve months with both compelling data from parallel clinical studies, regulatory interactions with health authorities the recruitment of key roles to the company and a second potentially lucrative collaboration agreement with pharma giant Boehringer Ingelheim. BioStock contacted the company's CEO, Rami Levin, to get his views on the first half of 2020 and to find out more about the plans for the coming 12 months. It is clear that Levin has high ambitions, both in the short and long term.